Preparation of LMWP-lysozyme and LMWP-BSA
The chemical conjugation procedures described above were also applicable to the preparation of LMWP-lysozyme and LMWP-BSA.
In vitro uptake in keratinocytes
Human keratinocytes (CCD 1106 KERTr, ATCC) were cultured as described in the Product Information Sheet from ATCC. Briefly, cells were cultured in KFM medium (Gibco, Invitrogen) in a humidified 5% CO 2 incubator at 37°C. Cells were seeded onto a 24-well plate at a density of 1×10 5 cells per well and grown to 70-80% confluence.
Various fluorescent dye labeled proteins and their LMWP-linked conjugates were then added to cells and incubated for 30 min. After thorough washing, cells were imaged using a fluorescence microscope (Olympus BX51).
Percutaneous protein delivery in mice
All the presented animal studies were approved by the University of Michigan Committee on Use and Care of Animals. LMWP-linked lysozyme, OVA, or BSA was applied to the Balb/c mouse skin. An area of dorsal skin was clipped free of hair 24 h prior to the topical application. After anesthetization, the clipped skin area was moistened with wet gauze for 10 min and extra water wiped off. The LMWP-linked protein conjugates were then applied to the clipped area, and after a 2-hour drug exposure the area was washed thoroughly. The antigen-applied skin was then harvested and processed by cryosection. Slides were imaged using a fluorescence microscope (Olympus BX51).
Lysozyme (MW 14 kDa) was labeled with Rhodamine B, whereas OVA (MW 44 kDa) and BSA (MW 66 kDa) were labeled with FITC.
to each well, and the plates were incubated for 15 min at RT. After addition of HCl to quench the reaction, absorbance at detection wavelength of 450 nm and reference wavelength of 570 nm was measured using a microplate reader (Bio-tek).
Transcutaneous immunization boosted existing immunity to OVA.
Mice were primed with OVA (50 µg per mouse) by IM injection, followed by booster administration, via topical application, of LMWP-OVA (250 µg per mouse) at the 2-and 4-week marks as described previously in the section above. Anti-OVA levels were determined by the ELISA method above, and the data were shown in Figure S1 .
Figure S1
Transcutaneous booster immunization of LMWP-OVA following the primer intramuscular immunization. Results showed that the combined immunization (IM+TI) was able to elicit high anti-OVA IgG responses at the levels statistically comparable to those obtained by the multi-dose intramuscular immunization (IM) ( 1 p = 0.0823). (n = 10) Figure S2 Characterization of LMWP-OVA by MALDI-TOF-MS. The calculated molecular weight of LMWP is 1880. Compared to OVA, the increased size of the LMWP-OVA conjugates indicated the addition of one LMWP.
